Tagprescribing

Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal?

S

AIDS Res Ther. 2018 Dec 12;15(1):26. doi: 10.1186/s12981-018-0213-z. Abstract The World Health Organization estimates that smoking poses one of the greatest global health risks in the general population. Rates of current smoking among people living with HIV (PLHIV) are 2-3 times that of the general population, which contributes to the higher incidence of non-AIDS-related morbidity and mortality...

Clinical Education Forum Recording: Contraception Update

C

SHINE SA, November 2018 Clinicians:  SHINE SA is pleased to present the following Clinical Forum by Dr Amy Moten on the topic of Contraception. This recording is available free of charge, and access is limited to three months only. This forum covers emergency contraception and new formulations of the Pill. 3 Category 2 RACGP Points can be awarded on completion of the forum. Recording length: 1...

HIV PrEP update & HIV prescriber update in Adelaide

H

ASHM, October 2018 HIV PrEP Update for GPs and Practice Nurses This training will provide GPs, Nurses, and Health Professionals working in primary care an update on strategies available for the prevention of HIV transmission, focusing on prevention particularly pre-exposure prophylaxis (PrEP). – Date Tuesday, 23 October 2018 – Venue Mercure Grosvenor, 125 North Terrace, Adelaide SA...

New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

N

European Medicines Agency, 18/05/2018 The European Medicines Agency (EMA) is evaluating preliminary results from a study which found 4 cases of birth defects such as spina bifida (malformed spinal cord) in babies born to mothers who became pregnant while taking dolutegravir. While EMA is assessing the new evidence it has issued the following precautionary advice: Dolutegravir HIV medicines should...

HIV PrEP available on PBS in Australia from 1 April / Links to Clinical Resources

H

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 21 March 2018 ASHM congratulates the Federal Health Minister, the Hon. Greg Hunt’s announcement of a landmark in HIV prevention to approve HIV-prevention drugs – tenofovir with emtricitabine, known as PrEP – on the Pharmaceutical Benefits Scheme from 1 April, thereby providing broader access for any doctor or general...

The updated 2017 ASHM HIV pre-exposure prophylaxis (PrEP) Guidelines

T

Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines.  These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...

Your sidebar area is currently empty. Hurry up and add some widgets.